Clinical trials: Population Medicine
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8
- Trial name
- NCT03819296
- Testing
- Best Practice, Biospecimen Collection, Endoscopic Procedure
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- M.D. Anderson Cancer Center
Heart Failure, Mortality
The Comparative Effectiveness Between ARNI and ACE Inhibitor/ARB Medication in Patient With HFrEF
This study aimed to evaluate the effectiveness, safety, and cost-effectiveness of ARNI and ACEi/ARBs in real-world practice. This study could find out what the unmet medical needs are in real world practice.
- Trial name
- PARADE-HF (NCT05329727)
- Testing
- Angiotensin receptor neprilysin inhibitor (ARNI), Renin-Angiotensin System Inhibitor (RAS inhibitor)
- Where
- South Korea
- Volunteers
- 1,000,000 people
- Sponsor
- Wonju Severance Christian Hospital
Generalized Anxiety Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
The purpose of this study is to evaluate the efficacy and safety of vortioxetine, once daily (QD), in adults with Generalized Anxiety Disorders.
- Trial name
- NCT00744627
- Testing
- Vortioxetine
- Where
- 38 sites in Estonia, Germany and 6 more
- Volunteers
- 301 people
- Sponsor
- Takeda
Cesarean Section, Hypotension Drug-Induced
Bupivacaine 5 mg vs 7.5 mg for Spinal Anesthesia in Cesarean Delivery in Indonesian Population
This study aims to evaluate the efficacy of hyperbaric 5 mg bupivacaine + fentanyl 25 mcg versus hyperbaric 7.5 mg bupivacaine + fentanyl 25 mcg to lower incidence of hypotension
- Conditions
- Cesarean Section, Hypotension Drug-Induced, Spinal Anesthesia, Postoperative Complications
- Trial name
- NCT03834454
- Testing
- Bupivacaine
- Where
- Indonesia
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Renal Impairment, Hepatic Impairment
Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment
The purpose of this study is to examine the effects of renal and hepatic impairment on TAK-272 pharmacokinetics with a single oral administration of TAK-272 in participants with renal or hepatic impairment.
- Trial name
- NCT02367872
- Testing
- TAK-272
- Where
- 4 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Takeda
Pharmacokinetics
Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status
BAY2327949 is currently under clinical development for chronic kidney disease. The goal of this study is to learn more about how the body absorbs, distributes and excretes the study drug when taken once per mouth as 30mg tablet.
- Trial name
- NCT04004195
- Testing
- BAY2327949
- Where
- 2 sites in Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug-naïve Patients With Parkinson's Disease, Apathy
Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study
Among the psychiatric symptoms observed in the premotor phase of Parkinson's disease (PD) and/or in "de novo" patients, apathy is relatively frequent (estimated to 23%).
- Trial name
- NCT01765257
- Testing
- AZILECT®
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Clermont-Ferrand
Helicobacter Infections, Stomach Neoplasms
Helicobacter Pylori Eradication to Prevent Gastric Cancer
Gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related death in the world. In China, more than 390,000 new patients are diagnosed with gastric cancer and more than 300,000 patients…
- Trial name
- NCT01133951
- Testing
- OAC triple therapy
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Jie-Jun Wang
Drug-drug Interaction
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
This drug-drug interaction study will evaluate the impact of two different acid reducing agents (from two different drug classes) co-administered with a single dose of telotristat ethyl.
- Trial name
- NCT03302845
- Testing
- Omeprazole 40 MG, Famotidine 40 mg, Telotristat ethyl 250 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Lexicon Pharmaceuticals
Hypertension
Implementing a Multi-component Hypertension Control Strategy in Rural Pakistan
This is a research about cardiovascular disease risk reduction: a comprehensive package for the reduction of risk in Sindh, Pakistan.
- Trial name
- NCT06726057
- Testing
- Imlementation strategies in conjunction with multicomponent hypertension intervention, Multicomponent hypertension intervention
- Where
- Pakistan
- Volunteers
- 3,459 people
- Sponsor
- Aga Khan University
Neurocutaneous Syndromes, Neurofibromatosis Type 1 (NF1)
Precision Medicine for Neurocutaneous Syndromes in Western China
The goal of this observational study (retrospective multicenter cohort study) is to learn if precision medicine approaches-including genetic testing, targeted drugs, and coordinated care from multiple specialists-can improve…
- Conditions
- Neurocutaneous Syndromes, Neurofibromatosis Type 1 (NF1), Tuberous Sclerosis Complex (TSC), Sturge-Weber Syndrome (SWS)
- Trial name
- NCT07327164
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- West China Hospital
Coronary Artery Disease
BIOFLOW III Satellite-ELADIS Orsiro Stent System
This registry is a clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT02029092
- Where
- 14 sites in Spain
- Volunteers
- 404 people
- Sponsor
- C.E.M. Biotronik, S.A.
Type 2 Diabetes
Group Lifestyle Intervention for People With New Onset Type 2 Diabetes.
The purpose of the study is to assess whether weight loss achieved through a programme of intensive lifestyle management can result in enhanced production of Glucagon-Like Peptide-1 (GLP-1) together with improvements in the…
- Trial name
- GLP4Health (NCT00705952)
- Testing
- Lifestyle intervention
- Volunteers
- 22 people
- Sponsor
- The Royal Bournemouth Hospital
Multiple Sclerosis, Long COVID
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making…
- Conditions
- Multiple Sclerosis, Long COVID, Long Covid19, Obese
- Trial name
- NCT06171152
- Testing
- Liraglutide Pen Injector [Saxenda], Medication Diary
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Depression
The Effect of Group-based Lifestyle Medicine Intervention and CBT on Depressive Symptoms
The objective of this randomized controlled trial is to evaluate and compare the efficacy of group-based lifestyle medicine intervention and cognitive-behavioral therapy for depression (CBT-D) for Chinese adults with depressive…
- Trial name
- NCT05716464
- Testing
- Lifestyle medicine intervention, Cognitive-behavioral therapy for depression (CBT-D)
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Asthma
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects…
- Trial name
- NCT01165138
- Testing
- Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 70 sites in United States, Germany and 4 more
- Volunteers
- 612 people
- Sponsor
- GlaxoSmithKline
Osteoarthritis
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED)
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of osteoarthritis of the knee.
- Trial name
- NCT00092365
- Testing
- MK0966, rofecoxib
- Volunteers
- 413 people
- Sponsor
- Merck Sharp & Dohme LLC
Bronchial Asthma
Study of Efficacy of Lamotrigine in Therapy of Bronchial Asthma
The purpose of this study is to determine whether antiepileptic drug lamotrigine is effective in the treatment of chronic asthma.
- Trial name
- NCT00153244
- Testing
- Lamotrigine
- Volunteers
- 76 people
- Sponsor
- Centre of Chinese Medicine, Georgia
Diabetes Mellitus, Type 2
Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients
The objective of the current study is to investigate the efficacy, safety and tolerability of several doses of BI 1356 BS (0.5, 2.5 and 5 mg daily) compared to placebo over 12 weeks of treatment in patients with Type 2 diabetes…
- Trial name
- NCT00328172
- Testing
- BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily
- Where
- 71 sites in United States, Australia and 4 more
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Plaque Psoriasis
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045%…
- Trial name
- NCT05282771
- Testing
- Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
- Where
- United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.